FDA Grants Accelerated Approval to Tudriqev Plus Nivolumab for Advanced Cutaneous Melanoma After Anti-PD-1 Therapy – Replimune
Replimune Group announced that the FDA has granted accelerated approval for TudriqevTM (vusolimogene oderparepvec-wtpg), previously referred to as RP1, in combination with nivolumab for the treatment of adults… read more.




